Education
About Us
Working with TipRanks
Follow Us
DaVita (DVA)
NYSE:DVA
DVA Stock Chart & Stats
$140.83
$0.74(0.48%)
At close: 4:00 PM EST
$140.83
$0.74(0.48%)
Day’s Range― - ―
52-Week Range$101.00 - $178.38
Previous CloseN/A
Volume85.32K
Average Volume (3M)1.10M
Market Cap
$9.94B
Enterprise Value$21.61B
Total Cash (Recent Filing)$782.05M
Total Debt (Recent Filing)$15.05B
Price to Earnings (P/E)14.2
Beta0.49
Next Earnings
Apr 30, 2026EPS Estimate
2.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.40
Shares Outstanding70,600,000
10 Day Avg. Volume1,784,567
30 Day Avg. Volume1,103,302
Financial Highlights & Ratios
PEG Ratio-1.54
Price to Book (P/B)-15.02
Price to Sales (P/S)0.74
P/FCF Ratio7.46
Enterprise Value/Market Cap2.17
Enterprise Value/Revenue1.58
Enterprise Value/Gross Profit5.13
Enterprise Value/Ebitda8.18
Forecast
1Y Price Target
$162.50Price Target Upside15.39% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Capital Allocation And Earnings QualityActive share repurchases, combined with exclusion of one-time items from core earnings and cessation of recognizing prior losses, are expected to create a material earnings-per-share tailwind.
Treatment Adherence And Clinical InitiativesTargeted measures to reduce missed treatments, including prompt follow-up for patients who miss sessions and greater use of newer diabetes medications among dialysis patients, are expected to raise treatment volumes and improve outcomes.
Volume Growth And Patient OutcomesManagement expects a return to sustainable treatment-volume growth driven by improved patient outcomes and reduced mortality, supporting non-acquired volume expansion.
Bears Say
Regulatory And Policy RiskHealth-policy headwinds tied to Affordable Care Act provisions are expected to weigh on financial results, creating regulatory pressure on margins and reimbursement rates.
Technology Adoption ImpactTrials of new hemodiafiltration machines are not expected to meaningfully increase treatment volumes, limiting a technology-driven revenue boost.
DaVita News
DVA FAQ
What was DaVita’s price range in the past 12 months?
DaVita lowest stock price was $101.00 and its highest was $178.38 in the past 12 months.
What is DaVita’s market cap?
DaVita’s market cap is $9.94B.
When is DaVita’s upcoming earnings report date?
DaVita’s upcoming earnings report date is Apr 30, 2026 which is in 80 days.
How were DaVita’s earnings last quarter?
DaVita released its earnings results on Feb 02, 2026. The company reported $3.4 earnings per share for the quarter, beating the consensus estimate of $3.242 by $0.158.
Is DaVita overvalued?
According to Wall Street analysts DaVita’s price is currently Undervalued.
Does DaVita pay dividends?
DaVita does not currently pay dividends.
What is DaVita’s EPS estimate?
DaVita’s EPS estimate is 2.34.
How many shares outstanding does DaVita have?
DaVita has 70,600,000 shares outstanding.
What happened to DaVita’s price movement after its last earnings report?
DaVita reported an EPS of $3.4 in its last earnings report, beating expectations of $3.242. Following the earnings report the stock price went up 21.171%.
Which hedge fund is a major shareholder of DaVita?
Currently, no hedge funds are holding shares in DVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DaVita Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$162.50 (15.39% Upside)
$162.50 (15.39% Upside)
Blogger Sentiment
Bullish
DVA Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 15.1%
Last 30 Days ▲ 10.7%
Last 30 Days ▲ 10.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.74%
Trailing 12-Months
Company Description
DaVita
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
DVA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call balanced clear operational and financial progress—IKC clinical success and first profitable year, solid full-year adjusted OI and EPS, strong cash generation, disciplined capital returns, and constructive 2026 guidance—with persistent near-term challenges including treatment-volume pressure driven by elevated mortality, residual cyber-related losses, rising patient care costs (PCC +5.9% YoY), and payer headwinds from the expiration of enhanced premium tax credits (~$40M in 2026). Management emphasized actionable clinical initiatives and gave explicit multi-year targets, and the positive results and forward guidance slightly outweigh the headwinds.View all DVA earnings summariesDVA Revenue Breakdown
88.32% U.S. dialysis
11.68% Ancillary services
DVA Stock 12 Month Forecast
Average Price Target
$162.50
▲(15.39% Upside)
Technical Analysis
Fresenius Medical Care
―
HCA Healthcare
―
Encompass Health
―
Tenet Healthcare
―
The Ensign Group
―
Ownership Overview
Currently, No data available
---